Related Experiment Video
Updated: Jan 19, 2026

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
Collagen-binding basic fibroblast growth factor improves functional remodeling of scarred endometrium in uterine
Peipei Jiang1, Xiaoqiu Tang1, Huiyan Wang1
1Department of Obstetrics and Gynecology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China.
Abstract:
Intrauterine adhesion (IUA) is a common cause of uterine infertility and one of the most severe clinical features is endometrial fibrosis namely endometrial scarring for which there are few cures currently. Blocked angiogenesis is the main pathological change in the scarred endometrium. The fibroblast growth factor 2 (bFGF), a member of FGF family, is usually applied to promote healing of refractory ulcer and contributes to angiogenesis of tissues. In this study, the sustained-release system of bFGF 100 µg was administrated around scarred endometrium guiding by ultrasound every 4 weeks in 18 patients (2-4 times). Results showed that after treatment, the menstrual blood volume, endometrial thickness and the scarred endometrial area were improved. Histological study showed blood vessel density increased obviously. Three patients (3/18) achieved pregnancy over 20 gestational weeks. Therefore, administrating the bFGF surrounding scarred endometrium may provide a new therapeutic approach for the patients with endometrial fibrosis.
Related Concept Videos
08:20In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:07Electromyometrial Imaging of Uterine Contractions in Pregnant Women
05:26Establishing a Mouse Model of Thin Endometrium
08:29Measurement of Four Uterine NK Cell Subtypes Using Multiplexed Fluorescent Immunohistochemical Staining in Women with Repeated Implantation Failure
04:22Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
12:27Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

